Advanced Biotech Valuation With Mechanism-Aware PoS and Long-Hop Reasoning
Defend probability of success and valuation assumptions by tracing target biology, comparator trials, biomarkers, patents, sponsor history, market context, and evidence strength.
Decision questions
What this solution is built to answer.
Why should this asset's PoS differ from phase and therapeutic-area base rates?
Which evidence chains support or weaken the valuation assumptions?
How do target biology, comparator readouts, biomarkers, patents and sponsor execution change the investment view?
What trace should a deal team or board see before accepting the valuation case?
Capabilities
What ARiDA can run for this use case.
Long-hop traversal across disease, target, compound, trial, literature, patent, company and deal evidence.
Mechanism-aware probability of success that can incorporate target validation, comparator outcomes, biomarkers, readouts and sponsor execution.
Traceable assumption defense for rNPV, real options, Monte Carlo distributions and portfolio decisions.
Evidence-backed deliverables that connect the graph path to the valuation memo, model and board narrative.
Reasoning graphics
How ARiDA turns evidence chains into valuation defenses.
The cards below keep the original hop-chain visuals, but place them inside the standalone advanced valuation solution so the graphics support this specific use case.
- 01 / Target identification6-hop traversal
From a disease question to a druggable shortlist.
Disease genetics, mechanism support, druggability, FTO, assay readiness — all chained into a single ranked list.
DiseaseTargetsCompoundsLiteraturePatentsTrialsOutputDeliverableTarget shortlist scored on genetic support, druggability, freedom-to-operate, and assay readiness.
vs. PubMed keyword searchA keyword query for "disease X drug target" gives you a list of papers, not a ranked shortlist. No druggability scoring, no FTO check, no comparator landscape.
- 02 / Probability of success7-hop traversal
Mechanism-aware PoS, not historical base rates.
Beta-binomial priors anchored on the indication class, posterior updates on every readout. Updates as the science changes.
TargetsCompoundsComparator trialsLiteratureBiomarker evidenceDrug profileSponsor track recordOutputDeliverablePosterior PoS curve with 80% credible band and event-stamped milestones — every assumption traceable to its primary source.
vs. Hay 2014 / Wong-Siah-Lo 2019Base-rate methods compute PoS from two variables: phase × therapeutic class. They cannot incorporate target-specific genetic support, biomarker stratification, comparator readouts, or sponsor execution history.
- 03 / Competitive positioning5-hop traversal
Where the asset stands against the comparator set.
Trial endpoints, safety profiles, label breadth, payer precedent, IP runway — every dimension grounded in a primary record.
DrugsComparator trialsCompaniesPatents / LOELiteratureOutputDeliverableTPP radar + positioning scatter + LOE waterfall, all triangulated against named comparators.
vs. side-by-side label comparisonReading FDA labels in parallel tells you what the comparators say. It does not tell you trial-level efficacy / safety, real-world usage, payer access, or LOE timing.
- 04 / White-space mapping6-hop traversal
Indications nobody has filed in.
Disease landscape × active programs × MoA gaps × patent FTO — the indications still open for entry, with addressability scored.
DiseasesTargetsActive drugsPipelinePatents / FTOSponsor activityOutputDeliverableWhite-space map with indication addressability, IP runway, and competitive heat scored per cell.
vs. ClinicalTrials.gov keyword filterFiltering trial registries surfaces what is being run, not what is missing. Without the patent and target layers, true white space is invisible.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| valuation-enterprise-workflow | Advanced valuation with assumption defense | PoS trace, rNPV assumptions, real-options context, board narrative |
| competitive-landscape-deepdive | Comparator evidence and competitive pressure | TPP radar, comparator evidence, LOE and positioning analysis |
| patent-landscape-analysis | IP, FTO and exclusivity context | Patent families, assignees, jurisdictions, filing trends |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Mechanism-aware PoS rationale with source trace.
Valuation assumption register tied to evidence paths.
Comparator and IP evidence pack for diligence.
Board-ready narrative explaining why the valuation case is or is not defensible.
Proof points
The page treats PoS as an evidence-updated judgment rather than a static base-rate lookup.
Long-hop reasoning makes visible which sources, links and inference order support the conclusion.
Advanced valuation connects science, competitive position, IP and finance in one decision trace.
FAQ
Common evaluation questions.
Is this different from standard rNPV?
Yes. rNPV is the financial wrapper. Advanced valuation focuses on defending the PoS and key assumptions with linked biological, clinical, competitive, IP and execution evidence.
Can this replace expert judgment?
No. It structures and traces the evidence so expert judgment is faster, more explicit and easier to defend in a committee setting.
Related solutions
Biotech Valuation
ARiDA runs evidence-backed biotech valuation workflows across single assets, multi-asset portfolios, platforms, fundraises, real options, Monte Carlo risk, and board dossiers.
Real Options Analysis
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Competitive Intelligence
Build competitive landscapes, TPP comparisons, patent-cliff views, market-share scenarios, and response plans from live web, trial, patent, literature, and database evidence.
Related reading
How to Produce an Investor-Grade Biotech Valuation Pack
An investor-grade valuation pack starts with an explicit argument about what must be true for the asset to be worth the number.
Why Board-Ready Outputs Require More Than Chat
Chat is a useful control layer, but board-ready biotech and pharma deliverables need production structure beneath the conversation.
Designing AI Research Systems for Biotech: Tools, Workflows, and Durable State
Biotech research systems need workflow structure, specialist lanes, files, and repeatable execution paths around the model.